CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at upcoming virtual healthcare industry conferences in October 2020.
A Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual investor conferences in October 2020.
CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications.
CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual conferences in August 2020.
CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M).
Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming virtual healthcare investor conferences in May and June 2020.